Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLS009
MIFTS: 48

Plasma Cell Neoplasm malady

Categories: Cancer diseases, Immune diseases, Blood diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Plasma Cell Neoplasm

About this section

Aliases & Descriptions for Plasma Cell Neoplasm:

Name: Plasma Cell Neoplasm 12 14 69
Plasma Cell Dyscrasia 12 69
Paraproteinemias 42 69
Plasma Cell Tumour 12
Plasmacytic Tumor 12
Multiple Myeloma 69
Plasmacytoma 69

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:6536
MeSH 42 D010265
SNOMED-CT 64 277576009 71390001
UMLS 69 C1136084
Sources

Summaries for Plasma Cell Neoplasm

About this section
MalaCards based summary : Plasma Cell Neoplasm, also known as plasma cell dyscrasia, is related to monoclonal paraproteinemia and refractory plasma cell neoplasm. An important gene associated with Plasma Cell Neoplasm is MYOM2 (Myomesin 2), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Dexamethasone and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are cellular and hematopoietic system

Sources

Related Diseases for Plasma Cell Neoplasm

About this section

Diseases related to Plasma Cell Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 124)
id Related Disease Score Top Affiliating Genes
1 monoclonal paraproteinemia 12.0
2 refractory plasma cell neoplasm 12.0
3 multiple myeloma 11.5
4 necrobiotic xanthogranuloma 11.2
5 plasmacytoma 10.7
6 alcoholic neuropathy 10.4 CD40LG CD79A
7 camptodactyly vertebral fusion 10.3 CD40LG CD79A
8 spinal polio 10.3 CD40LG CD79A
9 rabies 10.3 CD40LG CD79A
10 unilateral retinoblastoma 10.3 CD40LG CD79A
11 mesangial proliferative glomerulonephritis 10.3 CD40LG CD79A
12 delta chain disease 10.3 CD40LG CD79A
13 discitis 10.3 CD40LG CD79A
14 spinal canal and spinal cord meningioma 10.3 CD40LG CD79A
15 trichostrongyloidiasis 10.3 CD40LG CD79A
16 colloid adenoma 10.3 CD40LG CD79A
17 heart septal defect 10.3 CD40LG CD79A
18 cutaneous polyarteritis nodosa 10.3 CD40LG CD79A
19 mild pre-eclampsia 10.3 CD40LG CD79A
20 retinal microaneurysm 10.3 CD40LG CD79A
21 encephalitis 10.3 B2M MYOM2
22 pediatric meningioma 10.3 CD40LG CD79A
23 tonsil cancer 10.3 CD40LG CD79A
24 indomethacin antenatal infection 10.3 CD40LG CD79A
25 postcricoid region cancer 10.3 CD40LG CD79A
26 dendritic cell thymoma 10.3 CD38 CD79A
27 beach ear 10.3 CD40LG CD79A
28 acute kidney tubular necrosis 10.3 CD40LG CD79A
29 wound botulism 10.3 CD40LG CD79A MYOM2
30 atheroembolism of kidney 10.3 CD40LG CD79A
31 newcastle disease 10.3 CD40LG CD79A MYOM2
32 partial sensory epilepsy 10.3 CD40LG CD79A
33 xanthogranulomatous cholecystitis 10.3 CD40LG CD79A MYOM2
34 childhood vagina botryoid rhabdomyosarcoma 10.2 B2M CD79A MYOM2
35 jaw cancer 10.2 CD40LG MAG MYOM2
36 cannabis dependence 10.2 CD40LG MAG MYOM2
37 nerve compression syndrome 10.2 CD40LG MAG MYOM2
38 angiokeratoma 10.2 B2M CD40LG CD79A
39 ritscher-schinzel syndrome 1 10.2 CD40LG CD79A
40 glycogen storage disease viii 10.2 B2M CD40LG CD79A
41 pseudohypoparathyroidism 10.2 B2M CD40LG CD79A
42 central nervous system origin vertigo 10.2 B2M CD40LG CD79A
43 diabetic angiopathy 10.2 CD40LG CD79A
44 retinal degeneration 10.2 CD40LG CD79A IL6
45 lateral cystocele 10.2 CD40LG CD79A IL6
46 disease of mental health 10.2 CD40LG CD79A IL6
47 acute allergic sanguinous otitis media 10.2 B2M IL6 MYOM2
48 hallucinogen dependence 10.2 CD40LG CD79A IL6
49 keratomalacia 10.2 CD40LG CD79A IL6
50 nonspecific interstitial pneumonia 10.2 CD40LG CD79A IL6

Comorbidity relations with Plasma Cell Neoplasm via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Bronchitis
Chronic Kidney Failure Deficiency Anemia
Heart Disease Monoclonal Paraproteinemia
Neutropenia Osteoporosis

Graphical network of the top 20 diseases related to Plasma Cell Neoplasm:



Diseases related to Plasma Cell Neoplasm
Sources

Symptoms & Phenotypes for Plasma Cell Neoplasm

About this section

MGI Mouse Phenotypes related to Plasma Cell Neoplasm:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.23 PTPRC B2M CD19 CD38 CD40LG CD79A
2 hematopoietic system MP:0005397 10.18 MAEA MAG MYC PCSK5 PTPRC B2M
3 immune system MP:0005387 10.15 B2M CD19 CD38 CD40LG CD79A FGFR3
4 mortality/aging MP:0010768 10 B2M CD19 CD40LG FGFR3 IL6 MAEA
5 digestive/alimentary MP:0005381 9.98 B2M CD19 FGFR3 IL6 MYC PCSK5
6 integument MP:0010771 9.87 CD19 CD40LG FGFR3 IL6 MAEA MYC
7 neoplasm MP:0002006 9.7 B2M CD19 CD79A FGFR3 IL6 MYC
8 nervous system MP:0003631 9.7 B2M CD19 CD40LG CD79A FGFR3 IL6
9 renal/urinary system MP:0005367 9.17 CD19 CD40LG CD79A FGFR3 IL6 PCSK5
Sources

Drugs & Therapeutics for Plasma Cell Neoplasm

About this section

Drugs for Plasma Cell Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1001)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 111025-46-8 4829
4
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 79902-63-9 54454
5
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
6
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
7
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
8
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
9
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
10
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
11
Rifampin Approved Phase 4,Phase 1 13292-46-1 5458213 5381226
12
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 4053 460612
13
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
14
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
15
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
16
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
17
Tenofovir Approved, Investigational Phase 4,Phase 3 147127-20-6 464205
18
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
19
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
20
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24356-66-9 32326 21704
21
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
22
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
23
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-23-7 5754 657311
24
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
25
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
26
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
27
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
28
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
29
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
30
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
31
Vancomycin Approved Phase 4,Phase 3 1404-90-6 441141 14969
32
Thiotepa Approved Phase 4,Phase 2,Phase 1 52-24-4 5453
33
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
34
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 191732-72-6 216326
35
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
36
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
37
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
38
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
39
Panobinostat Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 404950-80-7 6918837
40
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
41
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
42
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
43
Theophylline Approved Phase 4 58-55-9 2153
44
Glyburide Approved Phase 4,Phase 3 10238-21-8 3488
45
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 155213-67-5 392622
46
Lopinavir Approved Phase 4,Phase 3 192725-17-0 92727
47
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
48
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
49
Phentolamine Approved Phase 4 50-60-2 5775
50
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091

Interventional clinical trials:

(show top 50) (show all 4161)
id Name Status NCT ID Phase
1 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4
2 Pseudohyponatremia of Multiple Myeloma is True Hyponatremia Unknown status NCT01425606 Phase 4
3 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4
4 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4
5 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
6 THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS Unknown status NCT02241876 Phase 4
7 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4
8 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4
9 Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin Unknown status NCT02443064 Phase 4
10 Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma Completed NCT02474563 Phase 4
11 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4
12 An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade Completed NCT01675245 Phase 4
13 Retrospective Survey of Re-treatment With Bortezomib Completed NCT01524445 Phase 4
14 A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure Completed NCT01241396 Phase 4
15 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma Completed NCT01083602 Phase 4
16 Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib Completed NCT01060202 Phase 4
17 A Retreatment Study With Bortezomib for Multiple Myeloma Completed NCT01030302 Phase 4
18 Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. Completed NCT01026701 Phase 4
19 Quality of Life in Multiple Myeloma Patients Treated With Bortezomib Completed NCT01021592 Phase 4
20 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4
21 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4
22 VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands Completed NCT00440765 Phase 4
23 ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. Completed NCT00440479 Phase 4
24 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4
25 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
26 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4
27 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
28 Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation Completed NCT01339572 Phase 4
29 Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) Completed NCT01005628 Phase 4
30 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4
31 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4
32 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4
33 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
34 REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
35 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4
36 Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients Completed NCT00195533 Phase 4
37 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4
38 Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation Completed NCT01738373 Phase 4
39 CAFE Study - Cancer Patient Fracture Evaluation Completed NCT00211237 Phase 4
40 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4
41 Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor Completed NCT01362985 Phase 4
42 Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis Completed NCT01217125 Phase 4
43 Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus Completed NCT00982358 Phase 4
44 Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome Completed NCT03122041 Phase 4
45 Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery Completed NCT00357656 Phase 4
46 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4
47 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4
48 Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus. Completed NCT00770835 Phase 4
49 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4
50 Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) Completed NCT01201811 Phase 4

Search NIH Clinical Center for Plasma Cell Neoplasm

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: paraproteinemias

Sources

Genetic Tests for Plasma Cell Neoplasm

About this section
Sources

Anatomical Context for Plasma Cell Neoplasm

About this section

MalaCards organs/tissues related to Plasma Cell Neoplasm:

39
B Cells, Bone, Bone Marrow, Thyroid, Neutrophil
Sources

Publications for Plasma Cell Neoplasm

About this section

Articles related to Plasma Cell Neoplasm:

(show top 50) (show all 52)
id Title Authors Year
1
Plasma cell neoplasm with plasmablastic morphology mimicking acute leukemia. ( 28057674 )
2017
2
Cytology of plasma cell rich effusion in cases of plasma cell neoplasm. ( 27756988 )
2016
3
Dual CD3 and CD4 positive plasma cell neoplasm with indistinct morphology: a diagnostic pitfall. ( 27133529 )
2016
4
Collision Tumor With Renal Cell Carcinoma and Plasmacytoma: Further Evidence of a Renal Cell and Plasma Cell Neoplasm Relationship? ( 27175345 )
2016
5
Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study. ( 26796980 )
2016
6
Plasma Cell Neoplasm Manifesting Initially as a Sub-Cutaneous Supra-Orbital Swelling. ( 26955130 )
2016
7
Osseous plasma cell neoplasm of the mandible for initial diagnosis of multiple myeloma: case report and literature review. ( 25861199 )
2015
8
Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains. ( 26339430 )
2015
9
Pediatric Pharyngeal IgD-positive Monoclonal Plasmacytoid and Plasma Cell Neoplasm. ( 25851555 )
2015
10
Image of the month : a rare presentation of a plasma cell neoplasm. ( 25333092 )
2014
11
Epstein-Barr virus-driven bone marrow aplasia and plasmacytosis mimicking a plasma cell neoplasm. ( 24405048 )
2014
12
Classical Hodgkin lymphoma with coexistant plasma cell neoplasm: A case report. ( 25308039 )
2014
13
Nodal involvement of extranodal marginal zone lymphoma with extreme plasmacytic differentiation (Mott cell formation) simulating plasma cell neoplasm and lymphoplasmacytic lymphoma. ( 25548763 )
2014
14
Practical diagnostic approaches to composite plasma cell neoplasm and low grade B-cell lymphoma/clonal infiltrates in the bone marrow. ( 24395190 )
2014
15
Crystal-storing histiocytosis with IgD I_-associated plasma cell neoplasm. ( 25028748 )
2014
16
Dysmegakaryocytopoiesis and maintaining platelet count in patients with plasma cell neoplasm. ( 23814762 )
2013
17
Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms. ( 23792270 )
2013
18
Plasma cell neoplasm associated chronic neutrophilic leukemia with membrane proximal and truncating CSF3R mutations. ( 24033109 )
2013
19
Intracellular and extracellular immunoglobulin crystals assuming a multitude of geometric shapes in an IgG-I> plasma cell neoplasm. ( 23720061 )
2013
20
CD3 expression in plasma cell neoplasm (multiple myeloma): a diagnostic pitfall. ( 23172088 )
2012
21
Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone. ( 22429092 )
2012
22
Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH. ( 22658896 )
2012
23
Familial haemophagocytic lymphohistiocytosis-related plasma cell neoplasm: a case report. ( 22774220 )
2012
24
Plasma cell neoplasm in conjunction with glioblastoma of the conus medullaris. ( 21325257 )
2011
25
Lower incidence of plasma cell neoplasm is maintained in migrant Chinese to British Columbia: findings from a 30-year survey. ( 21851219 )
2011
26
A quantitative analysis of genomic instability in lymphoid and plasma cell neoplasms based on the PIG-A gene. ( 20060400 )
2010
27
Mandibular radiolucency. Plasma cell neoplasm. ( 19906620 )
2009
28
Ophthalmic presentation of plasma cell neoplasm. ( 19617795 )
2009
29
Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. ( 17363561 )
2007
30
Clinical implication of centrosome amplification in plasma cell neoplasm. ( 16373658 )
2006
31
CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms. ( 16759389 )
2006
32
Myc translocations in B cell and plasma cell neoplasms. ( 16815105 )
2006
33
Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. ( 15735016 )
2005
34
Peripheral neuropathy associated with experimental plasma cell neoplasm in the mouse. ( 3029337 )
1987
35
Treatment of plasma cell neoplasm with recombinant leukocyte A interferon and human lymphoblastoid interferon. ( 3917376 )
1985
36
Thyroid-gland plasma cell neoplasm (plasmacytoma). ( 7027992 )
1981
37
An unusual case of a plasma cell neoplasm with an IgG3lambda myeloma and a gamma3 heavy chain disease protein. ( 412532 )
1978
38
Plasma cell neoplasm involving the thyroid. ( 638958 )
1978
39
Tumor cell invasion of hepatocytes in transplantable plasma cell neoplasm of mice. ( 4344454 )
1972
40
Ploidy fluctuations of mouse plasma-cell neoplasm MSPC-1 during serial transplantation. ( 5157581 )
1971
41
Enzymatic determinants of responsiveness of the LPC-1 plasma cell neoplasm to fluorouracil and fluorodeoxyuridine. ( 4254308 )
1970
42
Studies on the murine plasma-cell neoplasm, X5563. II. Accelerated immunologic reactivity to transplanted tumor induced in C3H mice by transferred immune rabbit cells. ( 6053557 )
1967
43
PLASMA CELL NEOPLASM ARISING IN A CAF MOUSE. CHARACTERISTICS AND RESPONSE TO CERTAIN CHEMOTHERAPEUTIC AGENTS. ( 14207853 )
1964
44
BIOCHEMICAL EFFECTS OF DUAZOMYCIN A IN THE MOUSE PLASMA CELL NEOPLASM 70429. ( 14096421 )
1963
45
Azaserine resistance in a plasma-cell neoplasm without change in active transport of the inhibitor. ( 13861221 )
1962
46
A study on globulin formation by plasma-cell neoplasm (5563) transplantable in mice. ( 13684805 )
1961
47
Distinctive myeloma globulins associated with a new plasma cell neoplasm of strain C3H mice. ( 13821296 )
1960
48
Alterations of gamma globulin with plasma cell neoplasm in mice. ( 13675239 )
1959
49
Growth inhibition of homografts of a plasma-cell neoplasm in cell-impenetrable diffusion chambers placed in hyperimmunized mice. ( 13792639 )
1959
50
Bence Jones proteinuria associated with a transplantable mouse plasma-cell neoplasm. ( 13821298 )
1959
Sources

Variations for Plasma Cell Neoplasm

About this section

Copy number variations for Plasma Cell Neoplasm from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17396 1 142600000 155000000 Gain Plasma-cell dyscrasia
Sources

Expression for Plasma Cell Neoplasm

About this section
Search GEO for disease gene expression data for Plasma Cell Neoplasm.
Sources

Pathways for Plasma Cell Neoplasm

About this section

Pathways related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Innate Immune System 62
Show member pathways
 13.8 B2M CD19 CD40LG CD79A FGFR3 IL6
2
Cytokine Signaling in Immune system 62
Show member pathways
 13.11 B2M CD40LG FGFR3 IL6 MYC NCAM1
3
PI3K-Akt signaling pathway 37
12.37 CD19 FGFR3 IL6 MYC
4
B cell receptor signaling pathway (KEGG) 1
Show member pathways
 12.15 CD19 CD79A MYC PTPRC
5
Epstein-Barr virus infection 37
12.04 CD19 CD38 MYC NUP214
6
NF-kappaB Signaling 4
12 B2M CD19 CD38 CD40LG CD79A NCAM1
7
Cell adhesion molecules (CAMs) 37
11.87 CD40LG MAG NCAM1 PTPRC
8
Spinal Cord Injury 1
11.78 IL6 MAG MYC
9
Hematopoietic cell lineage 37
11.66 CD19 CD38 IL6
10
Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers 61
11.64 CD19 CD79A IL6 NCAM1 PTPRC
11
Dendritic Cells Developmental Lineage Pathway 61
11.43 CD19 CD38 IL6 NCAM1 PTPRC
12
B Cell Development Pathways 61
11.39 CD19 CD38 CD40LG PTPRC
13
Primary immunodeficiency 37
11.19 CD19 CD40LG CD79A PTPRC
14
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 61
11.17 CD19 CD38 CD79A IL6 NCAM1 PTPRC
Sources

GO Terms for Plasma Cell Neoplasm

About this section

Cellular components related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.7 CD19 CD40LG CD79A FGFR3 MAEA MAG
2 cell surface GO:0009986 9.43 B2M CD38 CD40LG FGFR3 NCAM1 PTPRC
3 external side of plasma membrane GO:0009897 9.17 B2M CD19 CD40LG CD79A IL6 NCAM1

Biological processes related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.71 B2M CD38 IL6 MYC
2 positive regulation of T cell proliferation GO:0042102 9.43 CD40LG IL6 PTPRC
3 negative regulation of gluconeogenesis GO:0045721 9.37 IL6 MAEA
4 negative regulation of bone resorption GO:0045779 9.32 CD38 IL6
5 cellular response to prolactin GO:1990646 9.16 IL6 MYC
6 B cell proliferation GO:0042100 9.13 CD40LG CD79A PTPRC
7 B cell receptor signaling pathway GO:0050853 8.92 CD19 CD38 CD79A PTPRC
Sources

Sources for Plasma Cell Neoplasm

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....